Day One Biopharmaceuticals Inc
Day One Biopharmaceuticals — Investor Presentation (March 2026)
43 slides from Day One Biopharmaceuticals's investor presentation, Mar 2, 2026
Slide 1: Day One Biopharmaceuticals: Targeted therapies for people of all ages
Exhibit 99.1 Day One Biopharmaceuticals Targeted therapies for people of all ages March 2026
Slide 2: Disclaimer
Disclaimer This presentation and the accompanying oral commentary contain forward-looking statements that are based on our management’s beliefs and assumptions and on information currently available to our management. Forward-looking statements are inherently subject to risks and uncertainties, some
Slide 3: Developing new medicines for people of all ages with life-threatening diseases
Inspired by the urgent needs of children, Day One creatively and intentionally develops new medicines for people of all ages with life- threatening diseases 3
Slide 4: Bringing life-changing medicines to patients sooner
Bringing life-changing medicines to patients sooner Who we are • Commercial-stage biopharmaceutical company • Our goal is to develop and provide access to targeted new medicines to patients of all ages as rapidly as possible • Focused on advancing first- or best-in-class medicines for childhood and
Slide 5: Positioned for accelerating growth in 2026
Positioned for accelerating growth in 2026 We build long-term value by boldly advancing care for patients of all ages with high unmet needs 2026+ Growth • Solidify OJEMDA as 2L SOC in r/r pLGG 2025 Execution • 1L OJEMDA doubles pLGG ü 6 consecutive quarters of market opportunity double-digit growth
Slide 6: Our pipeline
Our pipeline Phase 1 Phase 1 Product / Product Therapeutic Phase 3/ Recent & Anticipated Dose Dose Phase 2 Approved Candidate Area Registrational Milestones Escalation Expansion 1 3-year follow-up data publication OJEMDA submission (Tovorafenib) BRAF-altered Q1 2026 2 FIREFLY-1 (pivotal Phase 2) Typ
Slide 7: Well positioned for sustained growth and value generation
Well positioned for sustained growth and value generation OJEMDA expansion Emi-Le OJEMDA $1B+ U.S. in R/R pLGG in 1L pLGG in ACC revenue opportunity in >$300M >$400M + >$500M + 3 high Durable, growing Expands earlier into Third, high-value unmet need revenue foundation treatment paradigm program ind
Slide 8: OJEMDA: Relapsed or refractory BRAF-altered pLGG
OJEMDA Relapsed or refractory BRAF-altered pLGG Nora Living with pLGG 8
Slide 9: Pediatric low-grade glioma: most common brain tumor in children
Pediatric low-grade glioma: The most common type of brain tumor in children A serious and life-threatening disease • For the majority of patients with pLGG in the relapsed setting, there is no standard of care, and until recently, no approved therapies pLGGs are chronic and • Up to 75% of pLGGs have
Slide 10: OJEMDA overview and U.S. prescribing information
Overview U.S. prescribing information for OJEMDA Available in tablet formulation and pediatric- friendly powder for oral suspension Indication OJEMDA is indicated for the treatment of pediatric patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma harboring a BRAF
Slide 11: OJEMDA is redefining the treatment paradigm in r/r pLGG
OJEMDA is redefining the treatment paradigm in relapsed or refractory pLGG • Clinical data reinforce OJEMDA’s role in the r/r pLGG treatment paradigm • Three-year follow-up data (Society for Neuro-Oncology 2025) reinforce durability of OJEMDA and align with how physicians manage pLGG Growing long-te
Slide 12: OJEMDA's durable clinical benefit supports adoption as 2L SOC
OJEMDA’s durable clinical benefit supports its adoption as 2L SOC 1 OJEMDA Clinical Profile FIREFLY-1: 3-Year Data • Median duration of response 19.4 months • Durable responses, retreatment 1 feasibility • Median time to next treatment 42.6 months • Data consistent with chronic use in • 77% of patie
Slide 13: Foundational U.S. opportunity in relapsed and frontline pLGG
Foundational U.S. opportunity for OJEMDA in both relapsed and frontline pLGG § Incident Therapeutic Build for New Illustrative pLGG Patient Flow Prevalence of Systemically-Treated Patients Under 25 Years ~26,000 pLGG Patients to be Treated in Frontline Setting Frontline (1L) Relapsed / Refractory (2
Slide 14: Runway for increased utilization in the 2L+ pLGG market
OJEMDA has meaningful runway for increased utilization in the 2L+ pLGG market Meaningful Runway for OJEMDA Increased Utilization ~1,100 unique r/r pLGG 2,3 • Current penetration reflects only a treatment decisions annually portion of the addressable r/r market, indicating substantial headroom for OJ
Slide 15: Commercial execution driving strong revenue growth
Commercial execution and clinical impact driving strong revenue growth OJEMDA Net Product Revenue OJEMDA Prescriptions (TRx) 1 1 $155.4M (+172%) in 2025 4,635 (+181%) in 2025 $52.8 1,394 2 2 (+37%) (+11%) 1,256 ~36% ~34% 1,062 CQGR CQGR $38.5 923 $33.6 $30.5 799 $29.0 610 $20.1 238 $8.2 Q2 Q3 Q4 Q1
Slide 16: Strong 2026 OJEMDA outlook
Commercial execution driving strong 2026 OJEMDA outlook OJEMDA U.S. Net Product Revenue Named Patient Program Net Revenue Transitioned to Ipsen >50% growth at $225-$250M the midpoint FF-1 3-Year Follow-Up OJEMDA 2026 Expected Data Fuels Expected Net Product Revenue 2026 Growth: $155.4M • Solidifying
Slide 17: Focused execution to solidify OJEMDA as 2L standard of care
Our strategy: focused execution to solidify OJEMDA as 2L standard of care Drive New Patient Starts Increase depth of prescribing through continued evidence generation that reinforces how OJEMDA’s clinical profile and benefits align with attributes physicians prioritize when treating pLGG patients* O
Slide 18: Intellectual Property and regulatory designations
Intellectual Property OJEMDA IP • Composition of matter patent of tovorafenib provides protection in summary and 1 the U.S. out to mid-2036 (with patent term extension) regulatory • Patent portfolio covers formulations, manufacturing methods, and uses of tovorafenib, with issued and pending applicat
Slide 19: 3-year follow-up data from the FIREFLY-1 trial
3-year follow- up data from the FIREFLY-1 trial studying OJEMDA Phase 2 FIREFLY-1 Trial 19
Slide 20: Observation period after OJEMDA cycles
After 26 OJEMDA cycles, patients could enter an observation period* Updated 3-year analysis † Time to next treatment, n=76 Subsequent anticancer therapy ‡ Treatment-free interval, n=39 or death Observation period OJEMDA Arm 1, n=77 Day 1 (no anticancer therapy) 26 cycles* (~24 months) Received 26 cy
Slide 21: Deep, durable responses with OJEMDA by IRC-assessed RAPNO
Deep, durable responses with OJEMDA evaluated by IRC-assessed RAPNO Updated 3-year analysis 3-year Exposure * Arm 1 (n=76) Completed ≥26 cycles of treatment, n (%) 44/76 (58) Response (IRC) † ORR, n (%) 40 (53) Best Overall Response, n (%) CR 0 PR 30 (39) MR 10 (13) ‡ SD 22 (29) PD 13 (17) NE 1 (1)
Slide 22: Many patients continued OJEMDA beyond radiographic progression
Many patients continued OJEMDA beyond RAPNO-defined radiographic progression by IRC Updated 3-year analysis † In the 3-year follow-up analysis, 38 patients had RAPNO-defined PD while on OJEMDA 100% 75% OJEMDA ‡ Reduced tumor size 50% beyond PD: at last scan prior to 100% (38/38) last dose, relative
Slide 23: RAPNO PFS and time to next treatment
RAPNO PFS demonstrates efficacy with OJEMDA; time to next treatment more accurately reflects the full clinical benefit Updated 3-year analysis § Median time to next treatment was 42.6 months (95% CI 36.7–NE) • RAPNO defines radiographic PD 1.0 as a ≥25% increase in tumor size ₸ from nadir —not basel
Slide 24: Tumor rebound was minimal in first months off therapy
Tumor rebound was minimal in the first 6 months off therapy Updated 3-year analysis 80 No tumor rebound (n=27) Tumor rebound (n=12)* Post-treatment 60 observation patients, n=39 40 3 months 6 months † † post-EOT post-EOT 20 Median time between prior scan 1.8 (0–4.2) and last dose, months (range) 0 ‡
Slide 25: Early evidence of retreatment activity
Early evidence of retreatment activity observed in the OJEMDA-retreated cohort Updated 3-year analysis Patients retreated with OJEMDA n=8 At time of data cutoff: • All 8 patients receiving OJEMDA -38.3 Median change, % (range)* (-80.9–0) retreatment were still on therapy † • Median tumor size was sm
Slide 26: 77% of patients treatment free for at least 12 months
77% of 39 patients were treatment free for at least 12 months; median treatment-free interval not yet reached Updated 3-year analysis 100 90 Post-treatment observation † patients n=39 80 70 Median duration of treatment, months (range) 24.6 (16.0–38.7) 60 50 Treatment free Median follow-up from last
Slide 27: No new safety signals in the 3-year update
No new safety signals were observed in the 3-year update Updated 3-year analysis Safety analysis set Safety analysis set Preferred term* (n=137) (n=137), n (%) Grade ≥3 TRAEs, n (%) Any 91 (66) All TEAEs 137 (100) Decreased growth velocity 46 (34) All TRAEs 136 (99) Anemia 19 (14) Grade ≥3 TEAEs 113
Slide 28: FIREFLY-2: Pivotal Phase 3 trial in front-line pLGG
FIREFLY-2 Pivotal Phase 3 trial of tovorafenib in front-line pLGG Bradon Living with pLGG since age 11 28
Slide 29: FIREFLY-2: 1L pLGG as largest future growth lever
FIREFLY-2: 1L pLGG approval represents the largest future growth lever for OJEMDA by doubling the commercial opportunity Estimated Annual 1 Treatment Decisions Key Value-Creation Milestones ~1,100 1L pLGG ~2,200 • FIREFLY-2 enrollment completion Total expected 1H 2026 Treatment • Topline data expect
Slide 30: Front-line expansion opportunity for tovorafenib in pLGG
Expansion into front-line treatment represents a meaningful expansion opportunity for tovorafenib in pLGG Trial design Endpoints • Randomized, global, registrational Phase 3 trial of monotherapy tovorafenib • Primary endpoint: ORR based on RAPNO-LGG criteria, assessed by vs SoC chemotherapy blinded
Slide 31: Emi-Le: B7-H4-targeted ADC
Emi-Le B7-H4-targeted antibody-drug conjugate (ADC) 31
Slide 32: Emi-Le: Transformational opportunity in ACC
Emi-Le: Transformational opportunity in Adenoid Cystic Carcinoma (ACC) High-impact clinical program parallels ~3-year line of sight to OJEMDA’s rapid development and potential approval and registration subsequent meaningful • Potential first-in-class program targeting a defined, treatment-resistant
Slide 33: Emi-Le Program Overview
Emi-Le Program Overview 1,2 Opportunity for Day One ACC patient population Emi-Le in ACC • Investigational B7-H4- • Annual U.S. incidence of • Emerging clinical data targeted ADC ~1,300 patients, conducive to rapid including: progression toward • Mechanism and registration modality well matched • AC
Slide 34: DAY301: PTK7-targeted ADC
DAY301 PTK7-targeted antibody-drug conjugate (ADC) 34
Slide 35: DAY301: Next generation ADC targeting PTK7
DAY301: Next generation ADC targeting PTK7 Potential first-in-class asset Antibody DAY301 Structure • High-affinity PTK7-targeted IgG1 antibody optimized for tumor penetration while 1 limiting off-target exposure Payload • High-potency topo-1 payload with 2,3 enhanced bystander activity Polysarcosin
Slide 36: PTK7: Well-suited as an ADC target
PTK7: Well-suited as an ADC target Clinically validated ADC target PTK7 overview PTK7 is Broadly Expressed Across Structure: single-pass transmembrane Multiple Solid Tumor Types protein in the pseudokinase family of 1,2 receptor tyrosine kinases Expression: overexpressed in a broad range of solid tu
Slide 37: DAY301: Improved tumor regression vs. benchmarks in preclinical models
DAY301: Improved tumor regression activity demonstrated vs. benchmarks in multiple preclinical models PDX 362797 SCLC PDX 362310 TNBC PDX LD1-200615 HNSCC H-score 210 H-score 255 H-score 120 DAY301 has been designed to maximize therapeutic index to overcome limitations of prior PTK7 programs and sta
Slide 38: DAY301: Initial Phase 1a/b clinical trial design
DAY301: Initial Phase1a/b clinical trial design Phase 1a: Monotherapy Phase 1b: Monotherapy 1 Key Design Elements Dose Escalation Dose Expansion and Optimization • Simon 2-stage design, initial dose optimization • BOIN design for efficiency followed by expansion into RD1 and RD2 cohorts of dose esca
Slide 39: Summary
Summary 39
Slide 40: Fourth quarter and full year 2025 financial results
Fourth quarter & full year 2025 financial results Three Months Ended Three Months Ended Full Year Ended Full Year Ended Financial Summary 12/31/25 12/31/24 12/31/25 12/31/24 ($ in millions) OJEMDA Net Revenue 52.8 29.0 155.4 57.2 License Revenue 0.9 0.2 2.8 73.9 Total Revenue $53.7 $29.2 $158.2 $131
Slide 41: Day One poised for a transformational 2026
Day One poised for a transformational 2026 Advancing Pipeline Deliver on 2026 net product revenue Advance Emi-Le: Deliver Phase 1 clinical guidance data by mid-2026, progress to later-stage development Complete FIREFLY-2 trial enrollment in 1H 2026, enabling mid-2027 data readout and Report Phase 1
Slide 42: Appendix
Appendix 42
Slide 43: Tovorafenib inhibits both BRAF fusions and BRAF V600 mutations
Tovorafenib inhibits both BRAF fusions and BRAF V600 mutations MAPK RAS-independent activation of the Tovorafenib is an investigational, oral, pathway MAPK pathway selective, CNS-penetrant, type II RAF inhibitor that was designed to inhibit both monomeric and dimeric RAF kinase RAS • Activity in tum
Day One Biopharmaceuticals — Investor Presentation (March 2026) on 6ix